Seminars in Oncology
Volume 33 , Pages 2-5 , February 2006

Goals of Treatment for Patients With Metastatic Breast Cancer

  • Ian Smith

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ian Smith, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK

References 

  1. O’Shaughnessy J , Miles D , Vukelja S , et al.   Superior survival with capecitabine plus docetaxel combination chemotherapy in anthracycline-pretreated patients with advanced breast cancer (phase 3 trial results) . J Clin Oncol . 2002;20:2812–2833
  2. Jassem J , Pienkowski T , Pluzanska A , et al.   Doxorubicin and paclitaxel vs fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer (Final results of a randomised phase III multicentre trial) . J Clin Oncol . 2001;19:1707–1715
  3. Stewart DJ , Evans WK , Shepherd FA , et al.   Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer (Superiority of doxorubicin) . J Clin Oncol . 1997;15:1897–1905
  4. Bishop JF , Dewar J , Toner GC , et al.   Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer . J Clin Oncol . 1999;17:2355–2364
  5. Nabholtz JM , Senn HJ , Bezwoda ER , et al.   Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy . J Clin Oncol . 1999;17:1413–1424
  6. Albain K , Nag S , Calderillo-Ruiz G , et al.   Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) (First report of overall survival) . Proc Am Soc Clin Oncol . 2004;22:5; (abstr 510)
  7. Mouridsen H , Gershanovich M , Sun Y , et al.   Superior efficacy of letrozole versus tamoxifen as first-line therapy for menopausal women with advanced breast cancer (Results of a phase III study of the International Letrozole Breast Cancer Group) . J Clin Oncol . 2001;19:2596–2606
  8. Mouridsen H , Sun Y , Gershanovich M , et al.   Final survival analysis of the double-blind, randomised multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer . Breast Cancer Res Treat . 2001;69:211; (abstr 9)
  9. Slamon DJ , Leyland-Jones B , Shak S , et al.   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med . 2001;344:783–791
  10. Geels P , Eisenhauer E , Bezjak A , et al.   Palliative effect of chemotherapy (Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer) . J Clin Oncol . 2000;18:2395–2405
  11. Cella DF , Tulsky DS , Gray G , et al.   The Functional Assessment of Cancer Therapy scale (Development and validation of the general measure) . J Clin Oncol . 1993;11:570–579
  12. Aaronson NK , Ahmedzai S , Bergman B , et al.   The European Organisation for Research and Treatment of Cancer QLQ-C30 (A quality-of-life instrument for use in international clinical trials in oncology) . J Natl Cancer Inst . 1993;85:365–376
  13. Coates AS , Hurny C , Peterson HF , et al.   Quality of Life Scores predict outcome in metastatic but not in early breast cancer . J Clin Oncol . 2000;18:3768–3774
  14. Goodwin PJ , Black JT , Bordeleau J , et al.   Health-related quality of life measurement in randomised clinical trials in breast cancer-taking stock . J Natl Cancer Inst . 2003;95:263–281
  15. Bottomley A , Therasse P . Quality of life in patients undergoing systemic therapy for advanced breast cancer . Lancet Oncol . 2003;3:620–628
  16. Kramer JA , Curran D , Piccart M , et al.   Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer (Quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist) . Eur J Cancer . 2000;36:1488–1497

PII: S0093-7754(05)00329-5

doi: 10.1053/j.seminoncol.2005.07.030

Seminars in Oncology
Volume 33 , Pages 2-5 , February 2006

Article Tools